



CONDENSED INTERIM
FINANCIAL STATEMENTS FOR
THE PERIOD ENDED DECEMBER
31, 2024



49 KM LAHORE MULTAN ROAD PAKISTAN
www.liven-pharma.com info@liven-pharma.com
+92-3-111-0-LIVEN

Table of Content

Company Information -----	3
Director’s Report-----	4
Auditor’s Review Report-----	8
Financial Statement -----	13

Company Information

Board of Directors

Mr. Atif Hussain
Chairman

Mr. Kaashif Hussain
Chief Executive Officer

Mrs Firdous Shakir
Executive Director

Mr. Umar Shami
Non Executive Director

Mr. Usman Shami
Non Executive Director

Mr. Ahmad Shoaib Hashmi
Independent Director

Mr. Syed Raza Abbas
Independent Director

Audit Committee

Mr. Ahmad Shoaib Hashmi
Mr. Umar Shami
Ms. Firdous Shakir

Human Resource & Remuneration Committee

Mr. Atif Hussain
Mr. Usman Shami
Mr. Kaashif Hussain

Chief Financial Officer Mr. Pir Muhammad Shah

Company Secretary
Mr. Muhammad Saeed

Head of Internal Audit
Mr. Saraan Saeed

External Auditors

Raenda Haroon Zakaria Amir Salman
Rizwan & Co

Legal Advisor

Saeed Associates

Share Registrar

F.D Registrar Services (pvt) Ltd

Bankers

Bank Al Habib Limited
Meezan Bank Limited

Registered Office

49 Km Lahore Multan Road Pakistan

+92-3-111-0-45836

info@liven-pharma.com

www.liven-pharma.com

Director Report

We are pleased to present the unaudited condensed interim financial statements of the Company for the six months ended December 31, 2024. These financial statements have been prepared in accordance with the requirements of the International Accounting Standard (IAS) 34 'Interim Financial Reporting' and the director report is prepared in accordance with section 227 of Companies Act, 2017 and Chapter XII of the Listed Companies (Code of Corporate Governance) Regulations, 2019.

Composition of Board

The Total Number of Directors are 7 as the following

1.	Male	6
2.	Female	1
Sr. No.	Category	Name
1	Independent Director	1. Mr. Ahmad Shoaib Hashmi 2. Mr. Syed Raza Abbass
2	Executive Director	1. Mr. Atif Hussain 2. Mr. Umar Shami 3. Mr. Usman Shami
3	Non Executive Director	1. Mr. Kaashif Hussain 2. Mr. Firdous Shakir

FINANCIAL HIGHLIGHTS

During the period under review, Liven Pharma Limited delivered a strong financial performance, driven by operational efficiencies and sustained demand in the pharmaceutical sector. The Company achieved a turnover of PKR 106 million, Gross profit improved to PKR 80.29 million, demonstrating effective cost management and enhanced production efficiencies. Profit after tax stood at PKR 119.233 million, because of the careful post financial management of merger reinforcing the Company's ability to generate sustainable profitability. Liven Pharma remains committed to further strengthening its financial position by leveraging growth opportunities through acquisitions and optimizing operational performance.

FUTURE CHALLENGES & PROSPECTS

Liven Pharma Limited (LIVEN) remains optimistic about its future growth, driven by strategic initiatives and favorable market conditions. The recent decrease in the KIBOR rate is expected to significantly reduce the company's financing costs, thereby enhancing profitability and cash flow management. Additionally, LIVEN is gearing up for its imminent expansion into the commercial market which will unlock new revenue streams and strengthen its market presence. With the pharmaceutical sector experiencing steady demand and the company's ongoing commitment to innovation, quality and operational efficiency, LIVEN is well-positioned to achieve sustained growth in the coming periods. The management remains focused on capitalizing on emerging opportunities and enhancing shareholder value, by introducing Multinational companies as technical and new product partner as well as gearing up to acquire an API manufacturing plant for the dynamic growth.

We are very much thankful for the cooperation and continuous support provided by the Regulatory Authorities, Shareholders, our Customers, Vendors, Employees and other stakeholders.

For and on behalf of the Board

Kaashif Hussain
CEO

Dated February 27th 2025.

Director Report

ہمیں خوشی ہے کہ ہم کمپنی کے غیر آڈٹ شدہ، مختصر عبوری مالیاتی بیانات پیش کر رہے ہیں، جو 31 دسمبر 2024 کو ختم عبوری مالیاتی رپورٹنگ کے '34 (AS) ہونے والے چھ ماہ کے لیے ہیں۔ یہ مالیاتی بیانات بین الاقوامی اکاؤنٹنگ معیار (تقاضوں کے مطابق تیار کیے گئے ہیں۔ ڈائریکٹر رپورٹ کمپنیز ایکٹ، 2017 کے سیکشن 227 اور لسٹڈ کمپنیز (کارپوریٹ کے مطابق تیار کی گئی ہے۔ XII گورننس کا ضابطہ) ریگولیشنز، 2019 کے چیپٹر

Composition of Board

The Total Number of Directors are 7 as the following

1.	Male	6
2.	Female	1
Sr. No.	Category	Name
1	Independent Director	1. Mr. Ahmad Shoaib Hashmi 2. Mr. Syed Raza Abbass
2	Executive Director	1. Mr. Atif Hussain 2. Mr. Umar Shami 3. Mr. Usman Shami
3	Non Executive Director	1. Mr. Kaashif Hussain 2. Mr. Firdous Shakir

FINANCIAL HIGHLIGHTS

جائزہ شدہ مدت کے دوران، لیون فارما لمیٹڈ نے ایک مضبوط مالیاتی کارکردگی کا مظاہرہ کیا، جو آپریشنل استعداد اور ملین کی کاروباری حجم حاصل کی، جبکہ PKR 106 دواسازی کے شعبے میں مسلسل طلب کی بنیاد پر تھی۔ کمپنی نے ملین تک بڑھا، جو مؤثر لاگت کے انتظام اور پیداواری استعداد میں بہتری کو ظاہر کرتا ہے۔ PKR 80.29 مجموعی منافع ملین رہا، جو انضمام کے بعد کی محتاط مالیاتی حکمت عملی کی بدولت کمپنی کی PKR 119.233 ٹیکس کے بعد منافع پائیدار منافعیت پیدا کرنے کی صلاحیت کو تقویت دیتا ہے۔ لیون فارما اپنی مالیاتی حیثیت کو مزید مستحکم کرنے کے لیے ترقی کے مواقع سے فائدہ اٹھانے اور آپریشنل کارکردگی کو بہتر بنانے کے لیے پرعزم ہے۔ مجھے بتائیں اگر آپ کسی قسم کی تبدیلی چاہتے ہیں!

FUTURE CHALLENGES & PROSPECTS

اپنی مستقبل کی ترقی کے بارے میں پرامید ہے، جو اسٹریٹیجک اقدامات اور موافق مارکیٹ (LIVEN لیون فارما لمیٹڈ) کی شرح میں کمی سے کمپنی کی مالیاتی لاگت میں نمایاں کمی متوقع ہے، جو منافع KIBOR حالات سے متاثر ہے۔ حالیہ تجارتی مارکیٹ میں اپنے قریبی توسیع کی تیاری کر رہا LIVEN اور نقدی بہاؤ کے انتظام کو بہتر بنائے گی۔ مزید برآں، ہے، جو نئی آمدنی کے ذرائع کھولے گا اور مارکیٹ میں اس کی موجودگی کو مستحکم کرے گا۔ دواسازی کے شعبے میں آنے والے عرصوں میں LIVEN مسلسل طلب اور کمپنی کی جدت، معیار اور آپریشنل استعداد کے مستقل عزم کے ساتھ، پائیدار ترقی حاصل کرنے کے لیے بہترین پوزیشن میں ہے۔ انتظامیہ ابھرتے ہوئے مواقع سے فائدہ اٹھانے اور شیئر ہولڈر کی قدر کو بڑھانے پر مرکوز ہے، جس میں کثیر القومی کمپنیوں کو تکنیکی اور نئے مصنوعات کے شراکت دار کے طور پر متعارف کرانا شامل ہے، نیز متحرک ترقی کے لیے مینوفیکچرنگ پلانٹ حاصل کرنے کی تیاری بھی شامل ہے۔ API ہم ریگولیٹری اتھارٹیز، شیئر ہولڈرز، اپنے صارفین، فروخت کنندگان، ملازمین، اور دیگر اسٹیک ہولڈرز کے تعاون اور مسلسل حمایت کے لیے بے حد شکر گزار ہیں۔

بورڈ کی جانب سے،

کاشف حسین

چیف ایگزیکٹو آفیسر

مورخہ: 27 فروری 2025

مجھے بتائیں اگر آپ کسی قسم کی تبدیلی یا مزید ترجمہ چاہتے ہیں



Ref: RHZASR/BAS/24-25/97
March 14, 2025

The Board of Directors
Liven Pharma Limited
49-KM, Multan Road, Phool Nagar District Kasur.

Honorable Members of the Board

Review of condensed interim financial statements of Liven Pharma Limited for the half year ended December 31, 2024

We are pleased to enclose the draft condensed interim financial statements of **Liven Pharma Limited** (the Company) for the half year ended December 31, 2024 prepared by management together with our draft auditors' review report thereon. These condensed interim financial statements have been initialed by us for the purpose of identification only.

May we apprise the Board of Directors (the Board) that until the auditors have signed their review report on the condensed interim financial statements, such condensed interim financial statements will remain and be deemed unreviewed.

We shall be pleased to sign the review report in the present or modified form after the Board has considered the matters raised in this letter and approved the condensed interim financial statements in their present or modified form and we have received the following:

- a) the condensed interim financial statements, with or without adjustments, approved by the Board and signed by the Chief Executive, Chief Financial Officer and a Director duly authorized on this behalf;
- b) signed copy of the minutes of the Audit Committee and the Board meetings in which financial statements are recommended and approved respectively;
- c) directors' report approved by the Board and signed by the Chief Executive and a Director of the Company, to be submitted to the Stock Exchange.
- d) signed copy of chairman's review;
- e) representation letter signed by the Chief Executive and the Chief Financial Officer of the Company;
- f) all information to be included and published in the form of interim report for our review under ISRE 2410;
- g) specific approvals regarding items in paragraph 2 below;
- h) specific representations regarding items in paragraph 3 below;

Reanda Haroon Zakaria Aamir Salman Rizwan & Company
Chartered Accountants

Page 1 of 5

Office No. 275, H-1 Block, M.A. Johar Town, Lahore - 54782, Pakistan
Tel: +92 (42) 3531 1524
Email: info@hzasrpk | Web: www.hzasrpk

Other offices in Karachi and Islamabad



Scanned with CamScanner



- i) considered the matters for specific attention of the Board outlined in paragraph 4 below; and

1. Responsibilities of the Auditors and the Board of Directors in relation to the financial statements

The responsibilities of the independent auditors in a usual examination of the financial statements are explained in Section 249 of the Companies Act, 2017 and International Standards on Review Engagements. While the auditors are responsible for forming and expressing their conclusion on the condensed interim financial statements, the responsibility for their preparation is primarily that of the Company's Board of Directors. The Board's responsibilities include the maintenance of adequate accounting records and internal controls, the selection and application of accounting policies and safeguarding of the assets of the Company. The review of the condensed interim financial statements does not relieve the Board of its responsibilities. Accordingly, our examination of the books of account and records should not be relied upon to disclose all the errors or irregularities, which are not material in relation to the condensed interim financial statements.

The Company may wish to publish its condensed interim financial statements and auditors' review report on its website. It is responsibility of the directors to ensure that any such publication properly presents the financial information and the auditors' review report. The management of the Company would advise us of any intended electronic publication before it occurs. We reserve the right to withhold consent to the electronic publication of the reports if the reviewed condensed interim financial statements or the auditors' review report are to be published in an inappropriate manner. Directors are responsible for the controls and security with regard to the website. Review of controls over the maintenance and integrity of the Company's website does not fall within the scope of the review of the condensed interim financial statements. The Directors are responsible for the process of distributing interim reports and other financial information to shareholders electronically.

2. Specific approvals

Before issuing our review report, we request the Board to consider and specifically approve the following:

- a) Addition amounting Rs. 585,300/- and Rs. 56,000/- were made in plant and machinery and intangible assets respectively.
- b) Trade discount amounting Rs. 1,135,965/- was provided to customers on sales.
- c) The Company has loan from director/CEO amounting to Rs. 11,049,173/- at half-year end. During the half year, the Company obtained an unsecured, and interest-free loan repayable on demand from Mr. Kashif Hussain Siddique, the Chief Executive of the Company, amounting to Rs. 11,049,173/- (refer to note 13);



- d) The deferred tax liability amounting to Rs. 9,611,285/- and deferred tax asset amounting to Rs. 7,888,990/- have been recognized in the condensed interim financial statements. The Company expects the availability of future taxable profits against which these deductible temporary differences can be utilized;
- e) Related party transactions as disclosed in note 18 to the financial statements.
- f) During the half year, the Company has issued 80,916,667 shares as part of scheme of arrangement to the owners of Liven Pharmaceutical (Private) Limited (merging entity).
- g) Change of nomenclature of the item as disclosed in the Note 20 to the condensed interim financial statements.
- h) Liven Pharma Limited (formerly Landmark Spinning Industries Limited) was previously preparing its financial statements on a non-going concern basis, has now adopted the going concern basis of accounting following its merger. In accordance with ISA 570 (Revised) – *Going Concern*, management has undertaken a going concern assessment. Based on the facts and circumstances disclosed in Note 1.2, management has concluded that the going concern assumption is appropriate for the preparation of the financial statements.
- i) Owing to the implementation of Scheme of Arrangement sanctioned by the Honorable High Court of Sindh, Karachi :
- Assets and liabilities of Liven Pharmaceutical (Private) Limited (merging entity) have been merged into assets and liabilities of Landmark Spinning Industries Limited (now Liven Pharma Limited- surviving entity) and goodwill amounting Rs. 27,292,828/- has been recognized.
 - the name of the Company changed from "Landmark Spinning Industries Limited" to "Liven Pharma Limited."
 - the principal line of business of the Company changed from "textile spinning" to "pharmaceuticals."
 - the registered office of the Company changed from "Sindh" to "Punjab."
 - Authorized share capital of the Company increased to Rs. 1 billion.

3. Specific representations

- a) The Board actively evaluates, observes and considers the factors necessary to keep the Company a going concern;
- b) All known actual or possible litigation and claims whose effects should have been considered when preparing condensed interim financial statements have been disclosed to the auditors and accounted for and disclosed in accordance with the applicable financial reporting framework.;
- c) There have been no related party transactions other than those disclosed in note 18 to the condensed interim financial statements;
- d) There have been no known instances of non-compliance or suspected non-compliance with laws and regulations, other than those disclosed, whose effects should have been considered when preparing condensed interim financial statements of the Company;
- e) The Board does not have knowledge of any actual, suspected or alleged fraud affecting the entity;
- f) The Company will initiate the process to either change the title of bank accounts that were in the name of merging entity to its name or close the bank accounts.
- g) The Company has made addition worth Rs. 971,502,959/- in its assets and Rs. 32,223,766/- in its liabilities as a result of scheme of arrangement from Liven Pharmaceuticals (Private) Limited (merging entity).
- h) The Company has complied with all laws and regulations in the implementation of merger scheme of arrangement as approved by the Honorable High Court of Sindh, Karachi.

4. Matters for attention of the Board

We would appreciate if the board could apprise us about the following matters:

- 1. In accordance with the requirements of International Standard on Review Engagements (ISRE) 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* we would qualify our conclusion owing to the effect of following matter:

The Company has not accounted for identifiable asset and liabilities assumed under scheme of merger (refer note 1.2) at their acquisition-date fair values, which constitutes a departure from applicable financial reporting framework. The related impact on these condensed interim financial statements could not be determined in absence of the relevant information.



2. Pakistan Stock Exchange (PSX) has inquired the Company regarding usual trading activity in the securities of the Company vide letter no. PSX/Gen-032 dated January 03, 2024.

We take the opportunity to express our appreciation of the courtesy and cooperation extended to us during the course of our audit by the staff and management of the Company.

Yours truly,


Reanda Haroon Zakaria Aamir Salman Rizwan & Company

Liven Pharma Limited
CONDENSED INTERIM STATEMENT OF FINANCIAL POSITION
AS AT DECEMBER 31, 2024

	Note	Un-audited Dec 31, 2024 (Rupees)	Audited June 30, 2024 (Rupees)
ASSETS			
NON-CURRENT ASSETS			
Property, plant and equipment	5	648,774,893	119,655,727
Intangible assets	6	37,694,074	-
Long term deposits	7	766,000	25,000
Total non-current assets		687,234,967	119,680,727
CURRENT ASSETS			
Stock in trade	8	130,511,934	-
Trade debts	9	129,880,286	-
Advances, deposits and prepayments	10	10,193,099	-
Bank balance	11	14,806,613	38,000
Total current assets		285,391,932	38,000
TOTAL ASSETS		972,626,899	119,718,727

The annexed notes 1 to 21 form an integral part of these condensed interim financial statements.

RH2025


 Chief Executive




 Director




 Chief Financial Officer





Liven Pharma Limited

CONDENSED INTERIM STATEMENT OF FINANCIAL POSITION AS AT DECEMBER 31, 2024

	Note	Un-audited Dec 31, 2024 (Rupees)	Audited June 30, 2024 (Rupees)
EQUITY AND LIABILITIES			
Share capital and reserves			
Authorized share capital			
100,000,000 (June 30, 2024: Rs.15,000,000) ordinary shares of Rs. 10/- each.		<u>1,000,000,000</u>	<u>150,000,000</u>
Issued, subscribed and paid-up share capital			
93,040,367 (June 30, 2024: 12,123,700) ordinary shares of Rs. 10/- each.		930,403,670	121,237,000
Capital reserve			
Surplus on revaluation on property, plant and equipment	12	-	38,056,592
Revenue reserve			
Accumulated loss		<u>(26,118,725)</u>	<u>(293,089,484)</u>
Total equity		<u>904,284,945</u>	<u>(133,795,902)</u>
LIABILITIES			
NON-CURRENT LIABILITIES			
Deferred taxation		<u>1,722,295</u>	<u>13,109,312</u>
Total non-current liabilities		<u>1,722,295</u>	<u>13,109,312</u>
CURRENT LIABILITIES			
Loan from related parties	13	11,049,173	238,507,287
Short term borrowings		14,014,065	-
Current portion of lease liabilities		395,413	-
Trade and other payables	14	19,071,880	1,898,030
Provision for taxation		<u>22,089,128</u>	<u>-</u>
Total current liabilities		<u>66,619,659</u>	<u>240,405,317</u>
Total liabilities		<u>68,341,954</u>	<u>253,514,629</u>
TOTAL EQUITY AND LIABILITIES		<u>972,626,899</u>	<u>119,718,727</u>
CONTINGENCIES AND COMMITMENTS			
	15		

The annexed notes 1 to 21 form an integral part of these condensed interim financial statements.

Rthas

[Signature]

Chief Executive

[Signature]

Director

[Signature]

Chief Financial Officer

Liven Pharma Limited
CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS
FOR THE HALF YEAR ENDED DECEMBER 31, 2024

	Note	Half Year Ended		Quarter Ended	
		Un-audited Dec 31, 2024 (Rupees)	Un-audited Dec 31, 2023 (Rupees)	Un-audited Dec 31, 2024 (Rupees)	Un-audited 2023 (Rupees)
Revenue		106,035,496	-	17,125,769	-
Cost of sales		(71,741,867)	-	(7,643,063)	-
Gross profit		34,293,629	-	9,482,706	-
Administrative and general expenses		(20,884,951)	(6,891,206)	(16,204,948)	(3,298,722)
Selling and distribution expenses		(2,765,370)	-	(2,765,370)	-
Finance costs		(3,150)	-	(3,150)	-
Operating profit / (loss)		10,640,158	(6,891,206)	(9,490,762)	(3,298,722)
Other income	16	119,295,890	-	-	-
Profit / (loss) before taxation		129,936,048	(6,891,206)	(9,490,762)	(3,298,722)
Taxation	17	10,702,111	1,304,562	-	652,282
Profit / (loss) after taxation		119,233,937	(5,586,644)	(9,490,762)	(2,646,440)
Profit / (loss) per share - basic and diluted		2.46	(0.46)	(0.10)	(0.22)

The annexed notes 1 to 21 form an integral part of these condensed interim financial statements.

RH2024


 Chief Executive




 Director




 Chief Financial Officer





Liven Pharma Limited

**CONDENSED INTERIM STATEMENT OF COMPREHENSIVE INCOME
FOR THE HALF YEAR ENDED DECEMBER 31, 2024**

	Half Year Ended		Quarter Ended	
	Un-audited 2024 (Rupees)	Un-audited 2023 (Rupees)	Un-audited Dec 31, 2024 (Rupees)	Un-audited 2023 (Rupees)
Profit / (loss) after taxation	119,233,937	(5,586,644)	(9,490,762)	(2,646,440)
Other comprehensive income				
Items that may be reclassified subsequently to profit or loss	-	-	-	-
Items that will not be reclassified to profit or loss	-	-	-	-
Total other comprehensive income for the period	-	-	-	-
Total comprehensive income / (loss) for the period	119,233,937	(5,586,644)	(9,490,762)	(2,646,440)

The annexed notes 1 to 21 form an integral part of these condensed interim financial statements.

RH-2024


Chief Executive Officer




Director




Chief Financial Officer





Liven Pharma Limited
CONDENSED INTERIM STATEMENT OF CHANGES IN EQUITY
FOR THE HALF YEAR ENDED DECEMBER 31, 2024

Particulars	Share capital	Capital reserve	Revenue reserve	Total equity
	Issued, subscribed and paid-up share capital	Surplus on revaluation of property, plant and equipment	Accumulated loss	
	Rupees			
Balance as at July 01, 2023 (audited)	121,237,000	44,444,434	(288,299,222)	(122,617,788)
Comprehensive income for the period				
Loss after taxation	-	-	(5,586,644)	(5,586,644)
Other comprehensive income	-	-	-	-
Total comprehensive loss for the period	-	-	(5,586,644)	(5,586,644)
Incremental depreciation net of deferred tax	-	(3,193,927)	3,193,927	-
Balance as at December 31, 2023 (un-audited)	121,237,000	41,250,507	(290,691,939)	(128,204,432)
Balance as at July 01, 2024 (audited)	121,237,000	38,056,582	(293,089,484)	(133,795,902)
Shares issued in accordance with scheme of merger	809,166,670	-	-	809,166,670
Impact of merger	-	-	109,680,240	109,680,240
Comprehensive income for the period				
Profit after taxation	-	-	119,233,937	119,233,937
Other comprehensive income	-	-	-	-
Total comprehensive income for the period	-	-	119,233,937	119,233,937
Surplus relating to disposal net of deferred tax transferred to retained earnings	-	(38,056,582)	38,056,582	-
Balance as at December 31, 2024 (un-audited)	930,403,670	-	(26,118,725)	904,284,945

The annexed notes 1 to 21 form an integral part of these condensed interim financial statements.

RAZOC

[Signature]



Chief Executive

[Signature]



Director



Chief Financial Officer

Liven Pharma Limited
CONDENSED INTERIM STATEMENT OF CASH FLOWS
FOR THE HALF YEAR ENDED DECEMBER 31, 2024

Note	Un-audited December 31, 2024 (Rupees)	Un-audited December 31, 2023 (Rupees)
CASH FLOWS FROM OPERATING ACTIVITIES		
Profit / (loss) before taxation	129,936,048	(6,891,206)
Adjustment for non-cash item		
Depreciation on property, plant and equipment	9,092,656	5,895,048
Amortization on intangible assets	942,922	-
Impact of merger	(16,075,241)	-
Gain on sale of property, plant and equipment	(85,424,621)	-
Liability written back	(33,871,269)	-
	(125,335,553)	5,895,048
Operating profit before working capital changes	4,600,495	4,898,890
Changes in working capital		
(Increase)/ decrease in current assets		
Stock in trade	(13,785,234)	-
Trade debts	(3,597,773)	-
Advances, deposits and prepayments	3,675	-
Decrease/ (increase) in current assets		
Trade and other payables	(656,802)	594,846
Net cash (used in) / generated from operating activities	A (13,435,639)	5,493,736
CASH FLOWS FROM INVESTING ACTIVITIES		
Adjustment of loan against the disposal of fixed assets	205,080,348	-
Payment for acquisition of property, plant and equipment	(585,300)	-
Payment for acquisition of intangible asset	(56,000)	-
Net cash generated from investing activities	B 204,439,048	-
CASH FLOWS FROM FINANCING ACTIVITIES		
Loan received from related parties	13 11,049,173	381,799
Adjustment of loan against the disposal of fixed assets	(204,636,018)	-
Net cash (used in)/generated from financing activities	C (193,586,845)	381,799
Net (decrease)/increase in cash and cash equivalents	A+B+C (2,583,436)	5,875,535
Cash and cash equivalents at the beginning of the period	38,000	26,983
Opening cash balances of amalgamated entity	17,352,049	-
Cash and cash equivalents at the end of the period	14,806,613	5,902,518

The annexed notes 1 to 21 form an integral part of these condensed interim financial statements.

RH2025


 Chief Executive




 Director




 Financial Officer





Liven Pharma Limited

**NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS
FOR THE HALF YEAR ENDED DECEMBER 31, 2024**

	Note	Un-audited December 31, 2024 (Rupees)	Audited June 30, 2024 (Rupees)
5 PROPERTY, PLANT AND EQUIPMENT			
Owned assets		642,703,219	33,759,052
Right-of-use assets		6,071,674	85,896,675
		<u>648,774,893</u>	<u>119,655,727</u>
5.1	The right-of-use assets includes motor vehicles and generators.		
6 INTANGIBLE ASSETS			
Goodwill under merger scheme		27,292,828	-
Intangible assets		10,401,246	-
		<u>37,694,074</u>	<u>-</u>
7 LONG TERM DEPOSITS			
Deposit with Central Depository Company		25,000	25,000
Deposit against generator set		411,500	-
Other security deposits		329,500	-
		<u>766,000</u>	<u>25,000</u>
8 STOCK IN TRADE			
Stock in trade		129,159,242	-
Stores, spares and loose tools		1,352,692	-
		<u>130,511,934</u>	<u>-</u>
9 TRADE DEBTS			
Trade debts - considered goods		129,880,286	-
10 ADVANCES, DEPOSITS AND PREPAYMENTS			
Advance to supplier		8,002,614	-
Other advances and prepayments		2,190,485	-
		<u>10,193,099</u>	<u>-</u>
11 BANK BALANCE			
Cash at bank - in current account		14,806,613	38,000

RH2024



Liven Pharma Limited

NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS FOR THE HALF YEAR ENDED DECEMBER 31, 2024

	Note	Un-audited December 31, 2024 (Rupees)	Audited June 30, 2024 (Rupees)
12 SURPLUS ON REVALUATION OF PROPERTY, PLANT AND EQUIPMENT			
Opening balance			
Surplus relating to disposal net of deferred tax transferred to retained earnings		38,056,582	44,444,404
		(38,056,582)	-
Transferred to retained earnings in respect of incremental depreciation charged during the period/ year- net of deferred tax		-	(6,387,852)
		-	38,056,582
12.1 Movement in revaluation surplus			
Opening balance			
Transferred to retained earnings in respect of Incremental depreciation charged during the year- net of deferred tax		51,165,894	60,162,869
		-	(6,387,852)
Related deferred tax of incremental depreciation charged during the year		-	(2,609,123)
		51,165,894	51,165,894
Related deferred tax			
Opening balance		13,109,312	15,718,435
Tax effect on incremental depreciation transferred to retained earnings		(13,109,312)	(2,609,123)
		-	13,109,312
		51,165,894	38,056,582
12.1.1 The revaluation surplus on property, plant and equipment is not available for distribution to the shareholders in accordance with section 241 of the Companies Act, 2017, now it is realized during the period on the disposal of assets.			
13 LOAN FROM RELATED PARTIES			
Hassan Ali Rice Export Company		-	217,959,012
Syndicate Minerals Export		-	20,548,275
Payable to CEO/director		11,049,173	-
		11,049,173	238,507,287

13.1 This represents the amount payable to CEO of the Company for expenses paid by him on behalf of the Company.

RH2024



Liven Pharma Limited
NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS
FOR THE HALF YEAR ENDED DECEMBER 31, 2024

	Note	Un-audited December 31, 2024 (Rupees)	Audited June 30, 2024 (Rupees)
14 TRADE AND OTHER PAYABLES			
Trade creditors			
Markup payable		16,097,531	-
Accrued expenses		90,364	-
		<u>2,883,985</u>	<u>1,898,030</u>
		<u>19,071,880</u>	<u>1,898,030</u>

15 CONTINGENCIES AND COMMITMENTS

There has been no significant change in the status of contingencies and commitments as reported in the annual financial statements for the year ended June 30, 2024.

	Note	Half Year Ended Un-audited December 31, 2024 (Rupees)	Half Year Ended Un-audited December 31, 2023 (Rupees)
16 OTHER INCOME			
Gain on disposal of property, plant and equipment		85,424,621	-
Liability written back		33,871,269	-
		<u>119,295,890</u>	<u>-</u>
17 TAXATION			
Current tax		22,089,128	-
Deferred tax		(11,387,017)	(1,304,562)
		<u>10,702,111</u>	<u>(1,304,562)</u>

18 TRANSACTIONS WITH RELATED PARTIES

Related parties comprise of associated undertakings, directors and their close family members, key management personnel and major shareholders of the Company. Transactions with related parties are as follows:

Name	Nature of transaction	Dec 31, 2024 (Rupees)	Dec 31, 2023 (Rupees)
------	-----------------------	--------------------------	--------------------------

Associated Companies

Hassan Ali Rice Export Company	Funds received for salaries and expenses	-	381,799
	Loan adjusted against disposal of fixed assets	(184,087,743)	-
	Liability written back	(33,871,269)	-
Syndicate Minerals Export	Loan adjusted against disposal of fixed assets	(20,548,275)	-



Liven Pharma Limited

**NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS
FOR THE HALF YEAR ENDED DECEMBER 31, 2024**

Description	Carrying amount			Fair Value			
	Fair value through profit or loss	Amortised Cost	Total	Level 1	Level 2	Level 3	Total
December 31, 2024 (Un-audited)				Rs.			
Financial liabilities							
Loan from related parties	-	11,049,173	11,049,173	-	-	-	-
Short term borrowings	-	14,014,065	14,014,065	-	-	-	-
Current portion of lease liabilities	-	395,413	395,413	-	-	-	-
Trade and other payables	-	19,071,680	19,071,680	-	-	-	-
	-	44,530,331	44,530,331	-	-	-	-

Description	Carrying amount			Fair Value				
	Fair value through profit or loss	Fair value through OCI	Amortised Cost	Total	Level 1	Level 2	Level 1	Total
June 30, 2024 (Audited)				Rs.				
Financial assets								
Long term deposits	-	-	25,000	25,000	-	-	-	-
Trade debts	-	-	-	-	-	-	-	-
Advances, deposits and prepayments	-	-	-	-	-	-	-	-
Bank balance	-	-	38,000	38,000	-	-	-	-
	-	-	63,000	63,000	-	-	-	-

Description	Carrying amount			Fair Value			
	Fair value through profit or loss	Amortised Cost	Total	Level 1	Level 2	Level 3	Total
June 30, 2024 (Audited)				Rs.			
Financial liabilities							
Loan from related parties	-	238,507,287	238,507,287	-	-	-	-
Short term borrowings	-	-	-	-	-	-	-
Current portion of lease liabilities	-	1,898,030	1,898,030	-	-	-	-
Trade and other payables	-	240,405,317	240,405,317	-	-	-	-

RH2-DS9



Liven Pharma Limited

NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS FOR THE HALF YEAR ENDED DECEMBER 31, 2024

20 CORRESPONDING FIGURES

The nomenclature for direct costs has been changed to cost of sales for better presentation.

21 DATE OF AUTHORIZATION

These condensed interim financial statements were authorized for issue on 14/3/25 by the Board of Directors of the Company.

Handwritten signature

Handwritten signature

Chief Executive



Handwritten signature

Director



Financial Officer